Overview

Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib

Status:
Active, not recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

This study aims at evaluating the efficacy of treatment with ponatinib in patients with chronic myeloid leukemia who are in a chronic phase and who previously received treatment with imatinib but resulted to be resistant to it.

Phase:

Phase 2

Details

Lead Sponsor:

Gruppo Italiano Malattie EMatologiche dell'Adulto

Treatments:

Imatinib Mesylate
Ponatinib